GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

I’m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’m wondering about Ozempic.

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

The surge of online weight-loss drug providers is unexpectedly fueling demand for a much older, once-stigmatized treatment: ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.